Rochester, NEW%20YORK2 Active Studies

Spinal Muscular Atrophy Clinical Trials in Rochester, NEW%20YORK

Find 2 actively recruiting spinal muscular atrophy clinical trials in Rochester, NEW%20YORK. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
736
Enrolling

Recruiting Spinal Muscular Atrophy Studies in Rochester

About Spinal Muscular Atrophy Clinical Trials in Rochester

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 2 spinal muscular atrophy clinical trials recruiting participants in Rochester, NEW%20YORK. These studies are seeking a combined 736 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Rochester — FAQ

Are there spinal muscular atrophy clinical trials in Rochester?

Yes, there are 2 spinal muscular atrophy clinical trials currently recruiting in Rochester, NEW%20YORK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rochester?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you about next steps.

Are clinical trials in Rochester free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rochester studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 2 active trials in Rochester are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov